세계 의약품용 젤라틴 시장 규모는 2023년 12억 5,000만 달러에서 2031년 19억 2,000만 달러에 달할 것으로 예상되며, 2024-2031년 예측 기간 동안 연평균 5.57% 성장할 것으로 예상됩니다. 시장을 형성하는 요인은 다양합니다. 여기에는 연구 투자 증가, 기술 발전, 돼지 젤라틴에 대한 높은 수요, 젤라틴 캡슐의 인기 증가, 유럽 시장에서의 수요 증가, 확장 기회를 찾는 기업 등이 포함됩니다.
시장의 중요한 촉진요인 중 하나는 연구 개발 전략에 대한 투자 증가입니다. 이러한 전략은 성장과 생산량 증가에 필요한 산업 혁신과 기술 발전을 촉진하는 데 도움이 되고 있습니다. 약물전달 및 젤라틴 기반 치료제의 기술 발전으로 젤라틴은 의약품에서 새로운 용도를 찾고 있습니다. 돼지 젤라틴에 대한 높은 수요도 세계 의약품용 젤라틴 시장의 성장을 촉진하는 주요 요인입니다. 돼지 젤라틴의 우수한 품질은 제약 산업에서 사용하기에 매우 적합합니다. 돼지 젤라틴의 용도는 기술 발전과 함께 증가하고 있으며, 이는 향후에도 이 제품에 대한 수요가 지속될 것임을 보여줍니다.
식물 유래 젤라틴 캡슐의 탄생 등 캡슐 기술의 발전으로 젤라틴 캡슐의 성능과 적응성이 향상되어 생산자와 고객 모두에게 더 매력적으로 다가오고 있습니다. 젤라틴 캡슐은 공기, 빛, 미생물의 번식 및 오염으로부터 내용물을 보호할 수 있기 때문에 세계 의약품용 젤라틴 시장에서 높은 수요를 보이고 있습니다. 유럽 시장도 세계 시장의 큰 성장 촉진요인입니다. 유럽연합(EU) 제약 시장의 성장과 강력한 제약 부문으로 인해 제약 젤라틴은 점점 더 필수 불가결 해지고 있습니다.
마지막으로, 기업은 다양성과 성장을 추구합니다. 새로운 젤라틴 브랜드의 도입과 기존 브랜드의 새로운 분야로의 성장은 이를 잘 보여줍니다. 이러한 요인들은 향후 몇 년 동안 세계 의약품용 젤라틴 시장의 추가 성장과 다양화를 촉진할 것으로 예상됩니다.
예를 들어, 2024년 5월, Kerala State Industrial Development Corporation Ltd(KSIDC)와 일본 Nitta Gelatin Inc.는 Nitta Gelatin India Ltd(NGIL)를 통해 케랄라 주에서 718만 달러 규모의 확장 프로젝트를 공동으로 시작했습니다. 이 프로젝트는 일본 다국적 기업이 최근 케랄라 주 총리가 방한했을 때 발표한 2,396만 달러의 투자 중 일부입니다.
연구 활동으로 시장 확대에 기여
업계의 연구개발(R&D) 활동이 활발해짐에 따라 세계 의약품용 젤라틴 시장은 대규모로 확대되고 있습니다. 제약사들은 생분해성 캡슐 및 첨단 약물전달 시스템과 같은 최첨단 젤라틴 기반 제품을 개발하기 위해 연구개발에 많은 자금을 투자하고 있습니다. 그 결과, GelTYR-Gelatin Tyramine의 대체품인 X-Pure-GelDAT와 같은 새로운 젤라틴 브랜드와 제품이 등장하고 있습니다. 또한, 젤라틴 생산 방법의 개발은 생산성과 가용성을 향상시켜 세계 의약품용 젤라틴 시장 확대를 촉진할 것으로 예상됩니다.
예를 들어, 2022년 1월, Darling Ingredients Inc.는 콜라겐 기반 솔루션의 세계 리더인 Rousselot Health 브랜드를 통해 캘리포니아에 위치한 재생 의학 연구 기관인 Terasaki Institute for Biomedical Innovation(TBI)과 파트너십을 체결했습니다. Rousselot과 TIBI는 이번 전략적 제휴를 통해 젤라틴 기반 치료제의 개발 및 임상 적용을 위해 협력할 예정이며, Rousselot은 TIBI에 X-Pure GelMA를 포함한 X-Pure 개질 젤라틴을 제공하고, 그 대가로 연구소와 임상시험을 통해 젤라틴이 어떻게 작용하는지에 대한 정보를 제공하게 됩니다.
기술의 발전은 시장 성장을 촉진할 것
나노기술, 3D 프린팅, AI, 머신러닝과 같은 기술 발전이 세계 의약품용 젤라틴 시장의 성장을 촉진하고 있습니다. 제약사들은 이러한 기술을 활용하여 기존 솔루션의 기능성과 품질을 능가하는 새로운 젤라틴 기반 제품을 생산하고 있습니다. 이러한 기술을 통해 젤라틴 기반 제품 개발 프로세스가 보다 비용 효율적이고 효율적으로 이루어지고 있습니다. 젤라틴은 유전자 치료, 약물전달 시스템, 조직 공학 등 다른 제약 분야에서도 널리 사용되고 있습니다. 이러한 기술들이 세계 의약품용 젤라틴 시장의 성장을 견인하고 있으며, 제약 산업에서 젤라틴의 사용은 앞으로도 계속 확대될 것으로 예상됩니다.
이 보고서는 세계 의약품용 젤라틴 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 및 전망 등을 제공합니다.
Global pharmaceutical gelatin market is projected to witness a CAGR of 5.57% during the forecast period 2024-2031F, growing from USD 1.25 billion in 2023 to USD 1.92 billion in 2031F. Various factors shape the global pharmaceutical gelatin market. These include increased investments in research, technological advancements, high demand for porcine gelatin, rise in the popularity of gelatin capsules, growing demand in the European market, and companies increasingly seeking expansion opportunities.
One significant driver of the global pharmaceutical gelatin market is the increased investment in research and development initiatives. These initiatives aid in promoting innovation and technological advancements in the industry, which is required for growth and increased production. Gelatin is finding new uses in pharmaceuticals thanks to technological developments in drug delivery and gelatin-based therapeutics. The high demand for porcine gelatin is another major factor driving the growth of the global pharmaceutical gelatin market. The superior qualities of porcine gelatin make it extremely desirable for use in the pharmaceutical industry. The applications of porcine gelatin are increasing with advancements in technologies, which indicates its continued demand for the product in the future.
Advancements are improving the performance and adaptability of gelatin capsules in capsule technology, such as the creation of plant-based gelatin capsules, which is increasing their appeal to both producers and customers. Gelatin capsules are in high demand in the global pharmaceutical gelatin market because of their ability to protect the contents from air, light, microbial growth and contamination. The European market is an additional significant factor boosting the growth of the global pharmaceutical gelatin market. Pharmaceutical gelatin is becoming more and more essential due to the European Union's growing pharmaceutical market and strong pharmaceutical sector.
Finally, businesses seek variety and growth. The introduction of new gelatin brands and the growth of established ones into new areas are clear indications of this. These factors are anticipated to fuel the further growth and diversification of the global pharmaceutical gelatin market in the upcoming years.
For example, in May 2024, the Kerala State Industrial Development Corporation Ltd (KSIDC) and Nitta Gelatin Inc. Japan jointly launched an expansion project in Kerala valued at USD 7.18 million through Nitta Gelatin India Ltd (NGIL). This project is a portion of the USD 23.96 million investment that the Japanese MNC disclosed during the Kerala Chief Minister's most recent visit to Japan.
Research Initiatives Propel the Expansion of the Market
Due to the industry's growing research and development (R&D) activities, the global pharmaceutical gelatin market is expanding significantly on a large scale. Pharmaceutical corporations are heavily spending on research and development to create cutting-edge gelatin-based products like biodegradable capsules and sophisticated drug delivery systems. New gelatin brands and products have emerged as a result, such as X-Pure-GelDAT, a substitute for GelTYR-Gelatin Tyramine. Furthermore, it is anticipated that developments in gelatin production methods will boost productivity and affordability, propelling the expansion of the global pharmaceutical gelatin market.
For example, in January 2022, Darling Ingredients Inc. established a partnership with the Terasaki Institute for Biomedical Innovation (TIBI), a regenerative medicine research institute situated in California, through its Rousselot Health brand, which is the world leader in collagen-based solutions. Rousselot and TIBI will work together on the creation of gelatin-based treatments and their clinical application through this strategic alliance. Rousselot will provide TIBI with X-Pure modified gelatins, including X-Pure GelMA, in exchange for information on how gelatin behaves in the laboratory and throughout clinical trials.
Technological Advancements Spur Growth of the Market
Advancements in technologies such as nanotechnology, 3D printing, artificial intelligence, and machine learning are propelling the growth of the global pharmaceutical gelatin market. Pharmaceutical companies are making use of these technologies to produce novel gelatin-based goods that surpass the functionality and quality of conventional solutions. These technologies have made the development process of gelatin-based products more cost-effective and efficient. Gelatin is also being extensively used in other pharmaceutical sectors such as gene therapy, drug delivery systems, and tissue engineering. The application of gelatin in the pharmaceutical industry will continue to expand due to these technologies propelling the growth of the global pharmaceutical gelatin market.
For example, in December 2023, the health brand Rousselot from Darling Ingredients Inc. announced that it had received US Patent and Trademark Office (USPTO) Patent No. US11795489B2, securing its intellectual property rights for StabiCaps, a specialized gelatin that enhances the stability and formulation of soft gel capsules to improve drugs' release.
High Demand for Porcine Gelatin Drives Market Growth
Due to the unique characteristics of gel-forming ability and the biocompatible nature of porcine gelatin, it is commonly used in the pharmaceutical industry, bolstering the growth of the global pharmaceutical gelatin market. Porcine gelatin is known for its clarity and flexibility, which makes it excessively useful in the manufacturing of hard gelatin capsules, and it also has other applications in the pharmaceutical industry, such as soft capsules, absorbable hemostats, etc. It is also used as a stabilizer in vaccines to preserve its efficacy and safety throughout the transit and storage process. Porcine gelatin is a preferred choice for pharmaceutical manufacturers because of its ease of production, nutritious content, and reduced cost.
For instance, to save production costs and waste related to soft gel leakers, Gelita AG, a global leader in gelatin, introduced Easyseal gelatin in December 2023. The novel solution can be obtained in swine form that complies with food and drug administration (FDA) requirements, and a corresponding China Drug Masterfile is available to facilitate entry into the Chinese market.
Rise in the Popularity of Gelatin Capsules Fuels Market Growth
There is a huge demand for gelatin capsules because of their versatility and ease of use. A significant demand for dietary supplements and nutraceuticals has been seen in the last few years, boosting the growth of gelatin capsules in the global pharmaceutical gelatin market. There is an increased demand for gelatin capsules made from alternative sources because of the rise in inclination towards vegan lifestyles and plant-based food. Gelatin capsules are becoming more customizable and effective due to technological and formulation advances, which appeal to both manufacturers and consumers.
In September 2023, Strides Pharma Science Limited declared that the United States Food and Drug Administration (USFDA) has approved Icosapent Ethyl Capsules, 0.5 gram and 1 gram, through its step-down wholly owned subsidiary, Strides Pharma Global Pte, Singapore. The product enhances the selection of authorized soft gelatin capsules offered by Strides.
Europe Shows Dominance in the Pharmaceutical Gelatin Market
Europe's pharmaceutical gelatin market has observed significant growth over the past couple of years. Companies are focusing on producing new products through research and development to cater to the growing demand that has arisen because of the growing burden of chronic diseases and the rise in the geriatric population. The global pharmaceutical gelatin market participants focus on continuous clinical trials to improve the efficacy of the medications. The global pharmaceutical gelatin market is expanding due to pharmaceutical companies and concerned authorities meeting patient requirements, surpassing challenges such as the limitations of sustainability and ethical concerns.
For example, Caldic B.V. and Nitta Gelatin, Inc. announced that they had reached an agreement to form a strategic distribution relationship in Europe. Through this partnership, Caldic will be able to provide a greater selection of specialty gelatin products and a broad range of collagen products that perfectly match its current line of products for the Food, Nutrition, Pharma, and Personal Care markets. Starting on January 1, 2024, Caldic and Nitta Gelatin collaborated to create prospects in Benelux, France, Iberia, Italy, Germany, Austria, Switzerland, United Kingdom, and Ireland.
Future Market Scenario (2024-2031F)
The significant shift toward biodegradable gelatin capsules is considered a major factor driving the growth of the global pharmaceutical gelatin market in the future.
The global pharmaceutical gelatin market will witness a significant rise in the use of gelatin in the functional food industry.
Advanced technologies like nanotechnology and 3D printing are going to drive the global pharmaceutical gelatin market. These technologies are used to produce innovative gelatin products with enhanced properties.
An increased use of gelatin in cosmetics and personal care products is expected to significantly drive the growth of the global pharmaceutical gelatin market.
Key Players Landscape and Outlook
One of the main factors driving the expansion of the global pharmaceutical gelatin market is partnerships and collaborations. These partnerships guarantee that many viewpoints are considered to meet the needs of a diversified nature. Through successful collaborations, companies in the industry share their expertise in developing new and innovative solutions, increasing efficiency, and reducing costs. Companies also often collaborate to increase their expansion in the global pharmaceutical gelatin market and reach new customers.
For example, in March 2024, BIO INX B.V., a leading material developer for 3D bioprinting, announced a strategic relationship with Rousselot GmbH, a global leader in gelatin- and collagen-based solutions included in Darling Ingredients Inc. This partnership represents a significant advancement in the field of 3D bioprinting. As part of this partnership, Rousselot's X-Pure gelatin biomaterials, which are known for their dependability and quality, will be distributed by BIO INX for research and technical purposes.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.